FindTrial
Sign In

Association of platelets glutamate transporter EAAT2 with early neurological deterioration in patients with acute ischemic stroke: a prospective study

Association of platelets glutamate transporter EAAT2 with early neurological deterioration in patients with acute ischemic stroke: a prospective study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200056056
Enrollment
Unknown
Registered
2022-01-31
Start date
2022-01-24
Completion date
Unknown
Last updated
2024-08-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute ischemic stroke

Interventions

Observation group:None

Sponsors

Zhujiang Hospital, Southern Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria for acute ischemic stroke, confirmed by head CT or MR; 2. Within 24h of onset; 3. Age > 18 years old; 4. Signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Taking antiplatelet drugs within 2 weeks before onset, such as aspirin, clopidogrel, prasugrel, ticagrelor, etc; 2. accompanied by serious complications, including severe infection, malignant tumor, serious diseases of the heart, lung, liver, kidney, and hematopoietic system; 3. Myocardial infarction, stroke, and vascular embolism occurred within 3 months before the onset of the disease.

Design outcomes

Primary

MeasureTime frame
Compensatory content of platelet glutamate transporter EAAT2;Plasma glutamate;early neurological deterioration;—

Countries

China

Contacts

Public ContactYang Guo

Zhujiang Hospital, Southern Medical University

guoyangmed@126.com+86 18665000973

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026